Marizev (Omarigliptin) 12.5 mg 10 pc/ 25 mg 20 pc

Indications

Marizev (Omarigliptin) is indicated for the treatment of adults with type 2 diabetes mellitus. It is used to improve blood sugar control in combination with diet and physical activity.

Key Information

• Drug Class:
  DPP-4 (Dipeptidyl Peptidase-4) Inhibitor.

• Dosage Form:
  Tablets with a dose of 25 mg (also available in 12.5 mg). Administered once a week orally.

• Mechanism of Action:
  Omarigliptin inhibits the DPP-4 enzyme, which degrades incretins — hormones that stimulate insulin release and reduce glucose production in the liver. This results in improved blood sugar regulation.

Usage

• Dosing Schedule: Taken once weekly, making it convenient and improving treatment adherence.
• Combination Therapy: Can be used alone or in combination with other antidiabetic medications.

Side Effects

• Upper respiratory tract infections.
• Headache.
• Nausea.
• Allergic reactions (rare).
• Risk of hypoglycemia (especially when combined with other glucose-lowering medications).

Contraindications

• Hypersensitivity to Omarigliptin or any component of the medication.
• Type 1 diabetes mellitus.
• Diabetic ketoacidosis.

Important Notes

• Medical Supervision: Regular monitoring by a healthcare provider is required before and during treatment.
• Storage: Store at room temperature, away from direct sunlight and moisture.

Marizev is an effective and convenient treatment option for type 2 diabetes, offering a simple dosing schedule (once weekly) and minimal side effects, making it a preferred choice for many patients.